Specialty Pharmacy

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The onus to have properly-trained pharmacists has shifted from the specialty pharmacy to the individual.

New research has associated certain health problems with later diagnosis of multiple sclerosis.

The report compared the tolerability and safety of CGRP inhibitors—erenumab, fremanezumab, and galcanezumab—to no preventive treatment or commonly-used preventive therapies.

Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.

The investigational treatment could benefit patients with amyotrophic lateral sclerosis whose disease is caused by mutations in the SOD1 gene.

Top news of the day from across the health care landscape.

This is the first approval that the FDA has granted as part of its new approaches to streamlining the development and review of oncology drugs.

Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) offers a new treatment option to adults living with HIV.

Study finds that specialty drug coverage policies are mostly inconsistent across health plans and many treatments have multiple restrictions to access.

Supplementation of the protein in the nerve cells prevented nerve degeneration, muscle atrophy, and paralysis in an amyloid lateral sclerosis mouse model.

Top news of the day from across the health care landscape.

New research has identified the origins of acute myeloid leukemia, which can be detectable more than 5 years before the disease develops.

Health care providers who offer HIV tests encourage patients to integrate preventive screenings into their health care routines.

Individuals treated for cancer in adolescence or young adulthood may be at higher risk for endocrine diseases, such as thyroid disease, testicular dysfunction, and diabetes.

Most individuals with multiple sclerosis experience pain as a symptom of the disease.

Top news of the day from across the health care landscape.

A new study provides insight into previously unknown details about the capsid that may have implications for the development of new drugs to treat the infection.

Officials with the US FDA are alerting health care professionals and patients of a voluntary recall of several, but not all, drug products containing the active ingredient valsartan.

Enzalutamide (Xtandi) is the first and only FDA-approved oral medication for both non-metastatic and metastatic castration-resistant prostate cancer.

Officials with the FDA have approved tecovirimat (TPOXX, SIGA), the first drug with an indication for the treatment of smallpox, to boost preparedness in the event of a bioterror attack

Study suggests that covering high-value medications benefits patients at no extra cost to insurers.

Researchers aim to determine whether an annual brain volume loss rate of less than 0.4% is a valid marker to assess treatment response.

Top news of the day from across the health care landscape.

The discontinuation of opioid therapy may address the rising death toll caused by drug overdoses while maintaining or potentially improving chronic, non-cancer pain in patients, according to a recent study.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses how to boost prescriber uptake of biosimilars.

Cognitive impairment is present in up to 70% of patients with multiple sclerosis, but can be difficult to completely evaluate in routine clinical practice.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.